FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies

February 10, 2021 – February 10, 2021 – The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.

Read More from FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies

FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

February 4, 2021 – February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.

Read More from FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

January 26, 2021 – January 26, 2021 – Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.

Read More from FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

December 10, 2020 – December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.

Read More from FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund